Self-Rating Procedures in the Evaluation of Antidepressants

Möller, Hans‐Jürgen; Zerssen, D. von

doi:10.1159/000284941

Cited by 41 publications

(9 citation statements)

References 44 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, our results correspond well with an earlier study, showing that physicians' ratings of functional impairment and symptom severity are partially predicted by depression severity [47]. Longitudinal studies show that disagreement between patients and physicians is more often experienced in acute phases of depression than after improvement [48]. This may account for part of the disagreement documented here.…”

Section: Discussionsupporting

confidence: 91%

Risk factors of symptom underestimation by physicians

Zastrow

Faude

Seyboth

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Risk factors of symptom underestimation by physicians

Zastrow

Faude

Seyboth

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

“…[8][9][10] Self-report instruments have a long tradition, especially in psychotherapy research, with the Beck Depression Inventory (BDI) being the most widely used questionnaire. [11][12][13] However, the BDI differs from clinician-rated scales not just in the mode of administration, but also in terms of what symptoms are assessed. This has prompted the development of parallel self-report and clinician-rated scales with matching content to facilitate the translation of evidence between research studies and clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Self-Report and Clinician-Rated Measures of Depression Severity: Can One Replace the Other?

et al. 2012

View full text Add to dashboard Cite

Background It has been suggested that clinician-rated scales and self-report questionnaires may be interchangeable in the measurement of depression severity, but it has not been tested whether clinically significant information is lost when assessment is restricted to either clinician-rated or self-report instruments. The aim of this study is to test whether self-report provides information relevant to short-term treatment outcomes that is not captured by clinician-rating and vice versa. Methods In genome-based drugs for depression (GENDEP), 811 patients with major depressive disorder treated with escitalopram or nortriptyline were assessed with the clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD), and the self-report Beck Depression Inventory (BDI). In sequenced treatment alternatives to relieve depression (STAR*D), 4,041 patients treated with citalopram were assessed with the clinician-rated and self-report versions of the Quick Inventory of Depressive Symptomatology (QIDS-C and QIDS-SR) in addition to HRSD. Results In GENDEP, baseline BDI significantly predicted outcome on MADRS/HRSD after adjusting for baseline MADRS/HRSD, explaining additional 3 to 4% of variation in the clinician-rated outcomes (both P < .001). Likewise, each clinician-rated scale significantly predicted outcome on BDI after adjusting for baseline BDI and explained additional 1% of variance in the self-reported outcome (both P < .001). The results were confirmed in STAR*D, where self-report and clinician-rated versions of the same instrument each uniquely contributed to the prediction of treatment outcome. Conclusion Complete assessment of depression should include both clinician-rated scales and self-reported measures.

show abstract

“…Therefore, depressed patients with severe symptomatology (e.g., at baseline) may underestimate their HRQOL [ 34 ]. Clinicians tend to recognize severe illness based on non-verbal evidence [ 36 ]. As patients’ conditions improve after treatment, their verbal reports become more important for less severe illness, because they are more capable of clearly identifying their problems [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine

et al. 2017

View full text Add to dashboard Cite

BackgroundThe aim of this study was to explore the relationships between depressive symptoms and health-related quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes.MethodsA total of 131 inpatients with MDD were enrolled to receive 20 mg of fluoxetine for 6 weeks. Symptom severity and adverse events were assessed at weeks 0, 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and UKU Side Effect Rating Scale, respectively. HRQOL was measured using the Short Form 36 (SF-36), including 8 subscales, physical component summary (PCS) and mental component summary (MCS), at baseline and week 6. Spearman’s coefficient, Cohen’s d, and multiple linear regression model were used for statistical analysis.ResultsOne hundred and six patients completing all measures at weeks 0 and 6 entered the analysis. HAMD-17 negatively correlated with SF-36 at baseline and week 6. The HAMD-17 had a larger effect size than SF-36. MCS, rather than PCS, showed statistically significant improvement. After using multiple linear regression analysis, age at onset, HAMD-17 score change, and number of adverse events reported during the trial period were related to MCS change after adjusting for confounding variables.ConclusionsFluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. Depressive symptoms had a greater extent of change than HRQOL. Clinicians must consider the negative effects of adverse events caused by antidepressants on the improvement of HRQOL.Trial registration http://clinicaltrials.gov, NCT01075529, retrospectively registered 24/2/2010.

show abstract

Self-Rating Procedures in the Evaluation of Antidepressants

Cited by 41 publications

References 44 publications

Risk factors of symptom underestimation by physicians

Risk factors of symptom underestimation by physicians

Self-Report and Clinician-Rated Measures of Depression Severity: Can One Replace the Other?

Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine

Contact Info

Product

Resources

About